stockrow
Friday 6 November 2026
Export BCRX’s income statement to Excel — free account
BioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
7.55
0.69
−8.37%
Follow BCRX
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.24 |
Piotroski F-Score |
2 | 5 | 2 | 3 | 2 | 5 | 3 | 4 | 3 | 7 |
P/S ratio |
17.79 | 18.24 | 40.32 | 8.17 | 69.96 | 15.78 | 7.86 | 3.52 | 3.45 | 1.87 |
Altman Z-Score |
(6.97) | (2.91) | (3.47) | (6.07) | (3.06) | (0.52) | (1.69) | (3.06) | (2.55) | 1.83 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.74 |
Altman Z″-Score (non-manufacturers) |
(23.23) | (10.93) | (18.03) | (16.46) | (9.26) | (3.73) | (5.90) | (8.05) | (8.82) | (2.63) |
Beneish M-Score |
(2.04) | (3.09) | (3.57) | (0.91) | (4.64) | 4.12 | (2.23) | (3.82) | (0.91) | (2.27) |
P/Operating CF |
(80.07) | (43.67) | (34.72) | (38.17) | (29.30) | (76.43) | (89.26) | (130.82) | (298.17) | 5.61 |
P/B ratio |
297.04 | 5.48 | 16.91 | 10.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
297.04 | 5.48 | 16.91 | 10.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
16.62 | 14.60 | 36.77 | 6.45 | 68.66 | 16.31 | 9.01 | 4.87 | 4.58 | 2.11 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.45 |
EV/Operating CF |
(8.20) | (8.94) | (8.20) | (3.51) | (9.05) | (18.03) | (15.08) | (16.96) | (39.68) | 5.31 |
EV/FCF |
(7.46) | (8.87) | (8.17) | (3.50) | (9.02) | (17.73) | (14.95) | (16.58) | (38.84) | 5.34 |
Quick Ratio |
1.20 | 1.65 | 1.59 | 1.73 | 2.95 | 5.21 | 4.51 | 2.99 | 2.49 | 1.95 |
Current Ratio |
1.23 | 1.68 | 1.65 | 1.78 | 3.06 | 5.46 | 4.90 | 3.31 | 2.63 | 2.06 |
Net Debt/EBITDA |
0.05 | 1.65 | 0.79 | 0.85 | 0.13 | (0.47) | (2.09) | (3.98) | (39.91) | 0.61 |
Debt/Assets |
59.79% | 14.57% | 22.24% | 30.64% | 83.50% | 100.86% | 134.08% | 162.04% | 169.39% | 93.53% |
Debt/Equity |
34.05 | 0.31 | 0.66 | 1.40 | (14.51) | (5.54) | (2.50) | (1.84) | (1.75) | (4.04) |
Asset Turnover |
0.25 | 0.19 | 0.13 | 0.30 | 0.07 | 0.34 | 0.48 | 0.62 | 0.89 | 1.74 |
Operating CF/Net income |
0.97 | 0.63 | 0.91 | 0.82 | 0.74 | 0.77 | 0.66 | 0.42 | 0.59 | 1.32 |
Capex/Depreciation |
(3.37) | (0.18) | (0.21) | (0.41) | (0.59) | (3.08) | 3.97 | 0.25 | 0.11 | 0.65 |
Interest Coverage |
(7.49) | (6.70) | (10.27) | (8.36) | (12.05) | (3.00) | (1.50) | (0.96) | (0.03) | 4.32 |
| (223.70%) | (154.16%) | (152.26%) | (248.94%) | (1,925.37%) | 291.59% | 123.07% | 60.40% | 19.08% | (88.68%) | |
| (51.97%) | (49.07%) | (62.29%) | (67.61%) | (71.69%) | (39.89%) | (43.42%) | (42.46%) | (17.65%) | 52.53% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (544.24%) | 0.00% | (4.71%) | 245.61% |
Return on Tangible Assets |
(244.55%) | (109.45%) | (187.47%) | (137.22%) | (81.16%) | (39.07%) | (58.89%) | (64.01%) | (33.00%) | 121.56% |
Average Days of Receivables |
121.44 | 88.65 | 75.87 | 165.52 | 177.17 | 68.31 | 68.19 | 62.72 | 64.03 | 44.57 |
Research and Development Expense of Revenue |
231.50% | 265.87% | 411.02% | 219.24% | 690.34% | 132.85% | 93.53% | 65.35% | 38.75% | 18.99% |
Selling, General and Administrative Expense of Revenue |
42.70% | 55.32% | 142.90% | 76.01% | 381.37% | 75.60% | 58.85% | 64.59% | 59.09% | 39.85% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
32.21% | 50.11% | 45.49% | 36.28% | 83.06% | 22.04% | 16.51% | 16.78% | 14.51% | 9.72% |
Graham Net Nets |
(0.05) | 0.07 | 0.02 | 0.07 | (0.02) | (0.05) | (0.15) | (0.41) | (0.35) | (0.14) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 1.67 | 3.72 | 6.89 | 7.93 | 4.72 | 0.00 |
Earnings Yield |
(11.79%) | (14.34%) | (12.14%) | (28.41%) | (14.50%) | (7.44%) | (11.62%) | (19.44%) | (5.72%) | 16.03% |
Free Cash Flow Yield |
(12.53%) | (9.02%) | (11.16%) | (22.55%) | (10.88%) | (5.83%) | (7.67%) | (8.34%) | (3.42%) | 21.10% |
Revenue per Share |
0.36 | 0.30 | 0.20 | 0.42 | 0.11 | 0.88 | 1.46 | 1.72 | 2.18 | 4.17 |
Operating CF per Share |
(0.73) | (0.49) | (0.90) | (0.77) | (0.81) | (0.79) | (0.87) | (0.49) | (0.25) | 1.66 |
Capex per Share |
(0.07) | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | (0.01) |
Free Cash Flow per Share |
(0.80) | (0.49) | (0.90) | (0.78) | (0.81) | (0.81) | (0.88) | (0.51) | (0.26) | 1.65 |
Cash per Share |
0.76 | 1.39 | 1.03 | 1.19 | 1.81 | 2.85 | 2.29 | 2.03 | 1.55 | 1.31 |
Shareholders Equity per Share |
0.02 | 0.99 | 0.48 | 0.33 | (0.12) | (0.60) | (1.58) | (2.37) | (2.30) | (0.57) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.02 | 0.99 | 0.48 | 0.33 | (0.12) | (0.60) | (1.58) | (2.37) | (2.30) | (0.57) |
Free Cash Flow |
(58.71) | (41.46) | (92.93) | (89.93) | (135.62) | (144.54) | (163.20) | (97.31) | (53.14) | 345.45 |
Working Capital |
12.63 | 50.56 | 44.88 | 72.01 | 218.15 | 462.42 | 410.99 | 345.98 | 261.58 | 208.28 |
Capital Expenditures |
(5.27) | (0.32) | (0.37) | (0.34) | (0.51) | (2.38) | (1.35) | (2.17) | (1.12) | (1.92) |
Net Current Asset Value |
(21.28) | 30.90 | 16.75 | 27.32 | (30.18) | (129.00) | (328.10) | (476.52) | (544.39) | (228.96) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.41 |
Capex to Sales |
0.20 | 0.01 | 0.02 | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.80 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.16 | 0.18 | 0.19 | 0.11 | 0.12 | 0.09 | (0.04) | (1.09) | (1.31) | (0.33) |
Cash ROIC |
(52.66%) | (18.23%) | (49.46%) | (39.14%) | (24.10%) | (14.49%) | (18.79%) | (12.59%) | (7.86%) | 54.26% |
Accounts Receivable Turnover |
3.51 | 3.38 | 3.97 | 3.69 | 1.16 | 8.26 | 6.77 | 6.16 | 6.63 | 9.41 |
Accounts Payable Turnover |
0.34 | 0.22 | 0.12 | 0.34 | 0.09 | 0.31 | 0.30 | 0.25 | 0.75 | 1.39 |
Inventory Turnover |
2.18 | 2.28 | 0.80 | 2.26 | 0.36 | 0.63 | 0.30 | 0.16 | 0.67 | 2.83 |
Average Days of Payables |
678.36 | 2,025.40 | 3,312.72 | 1,370.27 | 4,406.61 | 1,404.06 | 817.72 | 1,701.84 | 346.41 | 302.83 |
Days of Inventory on Hand |
79.45 | 159.81 | 703.14 | 161.54 | 1,657.57 | 797.30 | 1,568.28 | 2,336.37 | 240.59 | 103.29 |
Average Receivables |
7.51 | 7.44 | 5.21 | 13.22 | 15.40 | 19.03 | 40.01 | 53.77 | 68.01 | 92.94 |
Average Payables |
6.79 | 5.30 | 7.05 | 10.88 | 16.35 | 23.26 | 21.08 | 17.62 | 16.27 | 13.74 |
Average Inventory |
1.06 | 0.50 | 1.07 | 1.65 | 4.34 | 11.42 | 21.66 | 28.11 | 18.39 | 6.74 |
Average Assets |
106.10 | 134.05 | 162.55 | 161.06 | 255.00 | 461.43 | 569.08 | 533.48 | 503.69 | 502.29 |
Average Common Equity |
24.65 | 42.67 | 66.50 | 43.74 | 9.50 | (63.12) | (200.79) | (375.06) | (465.73) | (297.54) |
Columns are period end dates · fundamentals updated 4 Nov 2026